Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UM1AI068633 | U.S. NIH Grant/Contract | View source | |
| UM1AI068615 | U.S. NIH Grant/Contract | View source | |
| UM1AI106707 | U.S. NIH Grant/Contract | View source | |
| 38459 | Other Identifier | DAIDS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
| National Institute of Mental Health (NIMH) |
Not provided
Not provided
Not provided
Not provided
MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences of rectal microbicide placebo product application.
MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences of rectal microbicide placebo product application. At the start of each 4-week product use period, participants will receive either rectal inserts, rectal douches, or rectal suppositories and be instructed to use their assigned study product prior to each receptive anal intercourse (RAI) encounter during that period. Participants who do not have RAI in a given week will be asked to use the product without sex. There will be a 1-week washout period between each of the three product use periods. Participant follow-up will take approximately 3.5 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Product Sequence A | Other | Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period. |
|
| Product Sequence B | Other | Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period. |
|
| Product Sequence C | Other | Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period. |
|
| Product Sequence D | Other | Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo rectal insert | Behavioral | Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptability of Future Product Use | Using a 10-point scale (1=Very Unlikely; 10=Very Likely), participants were asked to answer the following question about their most recently used product: "Think about the positive and negative experiences you have had using the [study product] during the past 4-week period. If this [study product] was available and it provided some protection against HIV, how likely would you be to use it before receptive anal sex?". The endpoint was operationalized as binary, with scores 1 to 6 grouped as "low acceptability" and scores 7 to 10 as "high acceptability". | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
| Adherence to Placebo Products | Percentage of participants who used each study product as instructed | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
| Number of Grade 2+ Related Adverse Events | Number of all Grade 2 or higher related adverse events (AE) reported in the study as defined by the DAIDS AE Grading Table | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
Not provided
Not provided
Inclusion Criteria:
Men (cis or transgender) and TGW who are 18-35 years old at Screening, verified per site SOP.
Able and willing to provide written informed consent.
HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix II and willing to receive HIV test results.
Able and willing to provide adequate locator information, as defined in site SOP.
Available to return for all study visits and willing to comply with study participation requirements.
In general good health at Screening and Enrollment, as determined by the site Investigator of Record (IoR) or designee.
At Screening, history of consensual RAI at least three times in the past three months and expecting to maintain at least this frequency of RAI during study participation per participant report.
Willing to not take part in other research studies involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment).
For individuals who can get pregnant (i.e., TGM with a female reproductive system): a negative pregnancy test at Screening and Enrollment.
For individuals who can get pregnant: Per participant report at Enrollment, using an effective method of contraception for at least 30 days (inclusive) prior to Enrollment and intending to use an effective method for the duration of study participation; effective methods include:
Exclusion Criteria:
At Screening:
Anticipated use and/or unwillingness to abstain from using non-study rectally-administered medications and products during study participation, including personal lubricants containing nonoxynol-9 (N-9).
Note: The use of non-study personal lubricants and usual pre-RAI douches that do not contain N-9 is permitted during study participation.
Known adverse reaction to any of the components of the study products.
Participation in research studies involving drugs, medical devices, genital products, or vaccines within 30 days of the Enrollment Visit.
Participation in research studies involving rectal products (ever).
Per participant report, use of post-exposure prophylaxis (PEP) for potential HIV exposure within the 3 months prior to Enrollment.
In the 3 months prior to Enrollment, participant engagement in condomless RAI or RVI while not on PrEP with a partner who is HIVpositive and either not on ART or of unknown ART use status (by self report).
In the month prior to Enrollment, participant engagement in condomless RAI or RVI while not on PrEP with a partner who is of unknown HIV status and unknown PrEP/ART use status (by self-report).
Non-therapeutic injection drug use in the 12 months prior to Enrollment.
At either Screening or Enrollment, participant-reported symptoms and/or clinical or laboratory diagnosis of active anorectal or reproductive tract infection (RTI) requiring treatment per current WHO guidelines (http://www.who.int/hiv/ pub/sti/pub6/en/), or symptomatic urinary tract infection (UTI). Infections requiring treatment include: Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), symptomatic bacterial vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis.
Note: Otherwise eligible participants with a symptomatic UTI or an STI/RTI requiring treatment per current WHO guidelines may be retested during the screening process and if treatment is completed and symptoms have resolved within the screening window the participant may be enrolled.
Note: HSV-1 or HSV-2 seropositive diagnosis with no active lesions is permitted since treatment is not required.
For individuals who can get pregnant: Pregnant or breastfeeding at either Screening or Enrollment or planning to become pregnant during study participation.
For individuals who can get pregnant: Last pregnancy outcome 90 days or less prior to Screening.
Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.
Cisgender men, transgender men (TGM) and transgender women (TGW)
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José A Bauermeister, PhD, MPH | University of Pennsylvania | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alabama Clinical Research Site | Birmingham | Alabama | 35294 | United States | ||
| Bridge HIV Clinical Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Bauermeister J, Tingler R, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, et al. Acceptability and choice for three placebo products used with receptive anal sex. Conference on Retroviruses and Opportunistic Infections (CROI), Mar 6-10, 2021; Abstract # 716 | ||
| 38494656 | Derived | Bauermeister J, Lin W, Tingler R, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, Ho K, Kayange N, Phillips TP, Johnson S, Brown E, Zemanek J, Jacobson CE, Doncel GF, Piper J; MTN-035 Protocol Team for the Microbicide Trials Network. A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035. J Int AIDS Soc. 2024 Mar;27(3):e26219. doi: 10.1002/jia2.26219. | |
| 38066471 |
| Label | URL |
|---|---|
| Primary result abstract published by CROI | View source |
Not provided
Not provided
Recruitment took place at seven clinical research sites in four countries from April 2019 to March 2020
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Product Sequence A | Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| FG001 | Product Sequence B | Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| FG002 | Product Sequence C | Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| FG003 | Product Sequence D | Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| FG004 | Product Sequence E | Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| FG005 | Product Sequence F | Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period. Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Intervention (4 Weeks) |
| |||||||||||||
| Washout (1 Week) |
| |||||||||||||
| Second Intervetion (4 Weeks) |
| |||||||||||||
| Washout (1 Week) |
| |||||||||||||
| Third Intervention (4 Weeks) |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Study Participants | All study participants used rectal inserts, rectal douches, or rectal suppositories, each for a 4-week period, in six different sequencies (A-F) and were instructed to use their assigned study product prior to each RAI encounter during that period. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Acceptability of Future Product Use | Using a 10-point scale (1=Very Unlikely; 10=Very Likely), participants were asked to answer the following question about their most recently used product: "Think about the positive and negative experiences you have had using the [study product] during the past 4-week period. If this [study product] was available and it provided some protection against HIV, how likely would you be to use it before receptive anal sex?". The endpoint was operationalized as binary, with scores 1 to 6 grouped as "low acceptability" and scores 7 to 10 as "high acceptability". | Posted | Count of Participants | Participants | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
|
Adverse events were collected beginning at the time of enrollment (i.e., once a participant is randomized) through to the termination visit for an average of 15 weeks.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Rectal Insert | Participants used rectal inserts in a 4-week period and were instructed to use it prior to any RAI encounter during that period |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphadenopathy | Blood and lymphatic system disorders | Systematic Assessment |
First, self-reported responses tend to be favorable due to social desirability. Second, we recruited a convenience sample of participants willing to use each of the study products at least once per week as required by the protocol. Third, given the placebo nature of the three products used in our trial, we were unable to employ a biological confirmation method regarding participants' product use and adherence. Finally, we were unable to recruit the sexual partners of our study participants.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jose A. Bauermeister, PhD | University of Pennsylvania | 215-898-9993 | bjose@nursing.upenn.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 15, 2018 | Mar 16, 2021 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 25, 2021 | Mar 16, 2021 | SAP_002.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jun 15, 2018 | Mar 16, 2021 | ICF_001.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Product Sequence E | Other | Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period. |
|
| Product Sequence F | Other | Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period. |
|
|
| Placebo rectal suppository | Behavioral | Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
|
| Placebo rectal douche | Behavioral | Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI. |
|
| San Francisco |
| California |
| 94102 |
| United States |
| University of Pittsburgh Clinical Research Site | Pittsburgh | Pennsylvania | 15216 | United States |
| Blantyre Clinical Research Site | Blantyre | Malawi |
| San Miguel Clinical Research Site | San Miguel | 15088 | Peru |
| Wits Reproductive Health and HIV Institute Clinical Research Site | Johannesburg | 2038 | South Africa |
| Chiang Mai University HIV Prevention Clinical Research Site | Chiang Mai | 50202 | Thailand |
| Derived |
| Choi SK, Bauermeister J, Tingler RC, Johnson S, Macagna N, Ho K, Hoesley C, Liu A, Kayange N, Palanee-Phillips T, Chariyalertsak S, Gonzales P, Piper JM; MTN-035 Protocol Team. A latent trajectory analysis of young sexual and gender minorities' adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial). BMC Public Health. 2023 Dec 8;23(1):2464. doi: 10.1186/s12889-023-17368-y. |
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Ethnicity is collected from participants at the three U.S. Sites (N=96). | Only participants at the U.S. sites | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Race for U.S. sites and Ethnic group or tribe for non-U.S. sites | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | Rectal Suppository | Participants used rectal suppositories in a 4-week period and were instructed to use it prior to any RAI encounter during that period |
| OG002 | Rectal Douche | Participants used rectal douches in a 4-week period and were instructed to use it prior to any RAI encounter during that period |
|
|
| Primary | Adherence to Placebo Products | Percentage of participants who used each study product as instructed | Posted | Count of Participants | Participants | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
|
|
|
| Primary | Number of Grade 2+ Related Adverse Events | Number of all Grade 2 or higher related adverse events (AE) reported in the study as defined by the DAIDS AE Grading Table | Posted | Number | Adverse events | 14 weeks (three 4-week product use periods with 1-week washout periods between them) |
|
|
|
| 0 |
| 210 |
| 0 |
| 210 |
| 48 |
| 210 |
| EG001 | Rectal Suppository | Participants used rectal suppository in a 4-week period and were instructed to use it prior to any RAI encounter during that period | 0 | 209 | 0 | 209 | 45 | 209 |
| EG002 | Rectal Douche | Participants used rectal douches in a 4-week period and were instructed to use it prior to any RAI encounter during that period | 0 | 210 | 0 | 210 | 48 | 210 |
| Blepharitis | Eye disorders | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain lower | Gastrointestinal disorders | Systematic Assessment |
|
| Anal erythema | Gastrointestinal disorders | Systematic Assessment |
|
| Anal fissure | Gastrointestinal disorders | Systematic Assessment |
|
| Anal pruritus | Gastrointestinal disorders | Systematic Assessment |
|
| Anal skin tags | Gastrointestinal disorders | Systematic Assessment |
|
| Anorectal discomfort | Gastrointestinal disorders | Systematic Assessment |
|
| Anorectal ulcer | Gastrointestinal disorders | Systematic Assessment |
|
| Aphthous ulcer | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Defecation urgency | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Dyschezia | Gastrointestinal disorders | Systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | Systematic Assessment |
|
| Food poisoning | Gastrointestinal disorders | Systematic Assessment |
|
| Haematemesis | Gastrointestinal disorders | Systematic Assessment |
|
| Haemorrhoidal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Proctalgia | Gastrointestinal disorders | Systematic Assessment |
|
| Rectal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Rectal tenesmus | Gastrointestinal disorders | Systematic Assessment |
|
| Tooth impacted | Gastrointestinal disorders | Systematic Assessment |
|
| Toothache | Gastrointestinal disorders | Systematic Assessment |
|
| Hangover | General disorders | Systematic Assessment |
|
| Influenza like illness | General disorders | Systematic Assessment |
|
| Malaise | General disorders | Systematic Assessment |
|
| Pyrexia | General disorders | Systematic Assessment |
|
| Anal abscess | Infections and infestations | Systematic Assessment |
|
| Anal chlamydia infection | Infections and infestations | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | Systematic Assessment |
|
| Genital herpes simplex | Infections and infestations | Systematic Assessment |
|
| Influenza | Infections and infestations | Systematic Assessment |
|
| Molluscum contagiosum | Infections and infestations | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | Systematic Assessment |
|
| Oropharyngeal gonococcal infection | Infections and infestations | Systematic Assessment |
|
| Perineal abscess | Infections and infestations | Systematic Assessment |
|
| Pharyngotonsilitis | Infections and infestations | Systematic Assessment |
|
| Proctitis gonococcal | Infections and infestations | Systematic Assessment |
|
| Pustule | Infections and infestations | Systematic Assessment |
|
| Sexually transmitted disease | Infections and infestations | Systematic Assessment |
|
| Sinusitis | Infections and infestations | Systematic Assessment |
|
| Subcutaneous abscess | Infections and infestations | Systematic Assessment |
|
| Syphilis | Infections and infestations | Systematic Assessment |
|
| Tinea cruris | Infections and infestations | Systematic Assessment |
|
| Tonsilitis | Infections and infestations | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
|
| Urethritis | Infections and infestations | Systematic Assessment |
|
| Urethritis chlamydial | Infections and infestations | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Post procedural swelling | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Procedural pain | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Skin abrasion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Iron deficiency | Metabolism and nutrition disorders | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Idiopathic intracranial hypertension | Nervous system disorders | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | Systematic Assessment |
|
| Nephrolithiasis | Renal and urinary disorders | Systematic Assessment |
|
| Testicular pain | Reproductive system and breast disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Productive cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Cold urticaria | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Psoriasis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash papular | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash pruritic | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin hyperpigmentation | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin ulcer | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pharyngeal chlamydia infection | Infections and infestations | Systematic Assessment |
|
| Pharyngitis streptococcal | Infections and infestations | Systematic Assessment |
|
| pharyngitis | Infections and infestations | Systematic Assessment |
|
Not provided
| Missing |
|